RPG Life Sciences Ltd
₹ 2,481
3.32%
30 Jun
- close price
About
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]
Key Points
- Market Cap ₹ 4,103 Cr.
- Current Price ₹ 2,481
- High / Low ₹ 2,977 / 1,540
- Stock P/E 35.5
- Book Value ₹ 321
- Dividend Yield 0.81 %
- ROCE 32.8 %
- ROE 25.5 %
- Face Value ₹ 8.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 28.5% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
- Company has been maintaining a healthy dividend payout of 25.9%
Cons
- Stock is trading at 7.73 times its book value
- The company has delivered a poor sales growth of 11.7% over past five years.
- Earnings include an other income of Rs.95.3 Cr.
- Debtor days have increased from 35.3 to 48.5 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 236 | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | |
| 224 | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 408 | 453 | 493 | |
| Operating Profit | 12 | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 104 | 129 | 161 |
| OPM % | 5% | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% | 22% | 25% |
| 66 | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | 7 | 95 | |
| Interest | 3 | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 2 |
| Depreciation | 11 | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 16 | 17 | 21 |
| Profit before tax | 65 | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 92 | 118 | 233 |
| Tax % | 18% | 0% | 0% | 10% | 34% | 28% | 20% | 25% | 30% | 26% | 26% | 21% |
| 53 | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 68 | 88 | 183 | |
| EPS in Rs | 32.29 | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.00 | 110.79 |
| Dividend Payout % | 6% | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% | 29% | 30% | 18% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 63% |
| 5 Years: | 29% |
| 3 Years: | 31% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 56% |
| 3 Years: | 65% |
| 1 Year: | 51% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 24% |
| 3 Years: | 25% |
| Last Year: | 26% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 113 | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 |
| 15 | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | 0 | 0 | |
| 56 | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 138 | 127 | |
| Total Liabilities | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 |
| 106 | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 172 | |
| CWIP | 1 | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 91 | 127 |
| 89 | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 | |
| Total Assets | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6 | -2 | 33 | 7 | 15 | 46 | 50 | 58 | 65 | 91 | 94 | 78 | |
| 59 | -10 | -15 | -30 | -16 | -19 | -11 | -8 | -35 | -106 | -79 | -42 | |
| -54 | 12 | -18 | 23 | 0 | -26 | -39 | -10 | -14 | -17 | -20 | -27 | |
| Net Cash Flow | 0 | -0 | -0 | 1 | -1 | 0 | 0 | 40 | 17 | -32 | -5 | 9 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 | 27 | 31 | 48 |
| Inventory Days | 180 | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 | 203 | 200 | 159 |
| Days Payable | 176 | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 | 138 | 140 | 135 |
| Cash Conversion Cycle | 60 | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 | 91 | 90 | 72 |
| Working Capital Days | 51 | 76 | 54 | 50 | 62 | 53 | 46 | 53 | 47 | 33 | 25 | 45 |
| ROCE % | 2% | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% | 33% | 35% | 33% |
Documents
Announcements
- Closure of Trading Window 25 Jun
-
Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company
24 Jun - Company sent letters to shareholders with Annual Report web link as per SEBI regulations.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 Jun - Copy of Notice 18th AGM published in today''s newspaper in Business Standard (English) and Mumbai-Lakshadeep (Marathi), as intimation of completion of dispatch of Notice of …
-
Business Responsibility and Sustainability Reporting (BRSR)
23 Jun - Notice of RPG Life Sciences 18th AGM on July 16, 2025, with FY 2024-25 Annual and Sustainability Reports.
-
Reg. 34 (1) Annual Report.
23 Jun - Notice of RPG Life Sciences AGM on July 16, 2025, with FY 2024-25 annual and sustainability reports.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
Concalls
-
Jun 2025TranscriptNotesPPT
-
Apr 2025Transcript PPT REC
-
Nov 2024TranscriptNotesPPT
-
Sep 2024TranscriptPPTREC
-
Jul 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Oct 2023Transcript PPT
-
Jul 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Oct 2022Transcript PPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2019TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Jun 2016TranscriptNotesPPT
Business Overview:[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs